Market slacker Celgene does something good for a change, looking to turn the corner on past mishaps
At this point Celgene has been so battered over its poor performance of the past year you have to do a double take to convince yourself when something good happens to it.
But there was some considerable good news to be had in its Phase III study of franchise drug Revlimid in combination with Roche’s Rituxan in two forms — follicular and marginal zone — of indolent lymphoma.
According to researchers, they tracked a “highly statistically significant” improvement in progression-free survival in the study, opening the door to some near-term marketing applications that at least one prominent analyst speculates could be worth more than $1 billion in added sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.